AstraZeneca Pharma India Q1 FY27 Results: Revenue Rises 30% to ₹682.8 Crore

What Happened ?

AstraZeneca Pharma India reported 30% growth in Q1 FY2026–27 revenue from operations to ₹682.8 crore, reflecting continued momentum across its core therapy areas. The company attributed the performance to the strength of its portfolio, disciplined execution and its focus on improving patient outcomes in India.

The quarter also saw progress in regulatory approvals and strategic partnerships. AstraZeneca received approvals for multiple oncology therapies and advanced initiatives focused on earlier diagnosis, broader healthcare access and disease management.

key details

Therapy Area Performance:

• Oncology: Revenue reached ₹464.9 crore, representing 26% growth over Q1 FY26.
• Biopharmaceuticals: Revenue reached ₹161.9 crore, growing 36% YoY across CVRM, R&I and V&I.
• Rare Disease: Revenue stood at ₹14.4 crore, representing 35x growth compared with Q1 FY26.

Regulatory Milestones:

• Acalabrutinib – CLL/SLL: Received regulatory approval for use with venetoclax, with or without obinutuzumab, for previously untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma.
• Acalabrutinib – Mantle Cell Lymphoma: Received approval for use with bendamustine and rituximab for previously untreated adult patients with mantle cell lymphoma who are not eligible for autologous stem cell transplant.
• Trastuzumab Deruxtecan – HER2-positive Breast Cancer: Received approval for use with pertuzumab as first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.

Strategic Initiatives:

• Telangana AI-enabled Lung Cancer Screening: AstraZeneca signed an MoU with the Government of Telangana to introduce AI-enabled lung cancer screening across public healthcare facilities. The programme is expected to cover 20 public health facilities across urban and rural areas, using Qure.ai’s AI-powered chest X-ray solution. 
• K+ Connect: The company launched a pan-India multidisciplinary initiative focused on improving hyperkalaemia management among patients with heart failure and chronic kidney disease. 
• India Coronary Conquest 2026: AstraZeneca launched the initiative with STEMI India to strengthen evidence-based learning and peer exchange among interventional cardiologists through case-based learning and scientific collaboration.

Note:

• The Q1 performance was led by strong growth across all three disclosed therapy areas, with Biopharmaceuticals growing faster than Oncology and Rare Disease recording the sharpest percentage increase from its smaller base.
• The quarter also strengthened the company’s product portfolio through regulatory approvals and expanded its healthcare access initiatives.  

Risk Analysis

Summary:

• The source document does not provide a dedicated risk assessment. For investors, the key areas requiring monitoring are the sustainability of therapy-area growth, regulatory execution and the company’s ability to translate portfolio expansion and strategic initiatives into sustained commercial performance.

Key Risks:

• The company operates in prescription medicines across specialised therapy areas where regulatory approvals and market access remain important to product growth.
• Future performance will depend on continued momentum across Oncology, Biopharmaceuticals and Rare Disease.
• The disclosed quarterly financial summary does not provide EBITDA or PAT, limiting assessment of underlying earnings conversion from the available release.
• Strategic healthcare initiatives require effective implementation and adoption across participating healthcare systems.

Worst Case:

• Slower growth in key therapy areas, delays in regulatory or strategic initiatives, or weaker commercial execution could reduce the pace of future revenue growth.

Risk Level: Medium

Company Commentary

• Bhavana Agrawal, Chief Financial Officer & Director, said AstraZeneca Pharma India delivered 30% growth in the first quarter, taking revenue to ₹682.8 crore. She highlighted the company’s track record of consistent double-digit growth and its focus on strategically investing in opportunities that support sustainable long-term value creation. 
• Praveen Rao Akkinepally, Country President & Managing Director, said the company’s Q1 growth and momentum reflected the strength of its portfolio and its focus on expanding access to serve more patients in India. 
• AstraZeneca Pharma India said its strategy remains focused on addressing unmet medical needs, strengthening its presence across priority therapy areas and creating long-term value through science, innovation and sustainable growth.